Randomised Controlled Trial to Investigate the Effects of an Exercise Programme on Physical Performance and Quality of Life After a Bone Marrow Transplant
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Hematological Malignancies
- Sponsor
- Bayside Health
- Enrollment
- 66
- Locations
- 1
- Primary Endpoint
- Physical performance.
- Last Updated
- 10 years ago
Overview
Brief Summary
The hypothesis is that exercise will improve the physical performance and quality of life of bone marrow/ haemopoietic stem cell transplants.The aim of the trial is to provide definite clinical evidence as to which( if any) type of exercise is most beneficial for this patient population. It is also aimed at improving the provision of physiotherapy services to this group of patients.
Detailed Description
A three group, single blinded, randomised trial was designed to compare the effects of 1. aerobic plus active exercise and 2. aerobic plus resistance exercise to 3. control group of bone marrow/haemopoietic recipients not recieving exercise. The hypotheses being tested is that 1. Exercise improves the physical performance of transplants recipients. 2. Exercise improves the quality of life of these patients; 3. resisted exercise added to aerobic exercise increases muscle strength or lean muscle mass and 4. There are no adverse events during either form of exercise
Investigators
Eligibility Criteria
Inclusion Criteria
- •Recipient bone marrow transplant Alfred Hospital, Platelets \>= 20 x 10E9 / l Provide written consent, 30 days after a bone marrow transplant have an absolute neutrophil count of 1x10E9/l be in a stable medical condition
Exclusion Criteria
- •febrile neutropenia Have active graft versus host disease Have cardiomyopathy (ejection fraction \< 20%) require \> 28% oxygen
Outcomes
Primary Outcomes
Physical performance.
Time Frame: At 6 weeks
Quality of Life.
Time Frame: At 6 weeks
Anthropometry and Grip strength
Time Frame: At 6 weeks
Secondary Outcomes
- Heart Rate.(At 6 weeks)
- No adverse events during treatment.(At 6 weeks)